Bayer AG, the manufacturer of Cipro, is facing a growing number of product liability claims over the antibiotic’s alleged association with peripheral neuropathy and nerve damage. Cipro lawsuit plaintiffs accuse the company of concealing and downplaying this potential complication, and failing to provide adequate warnings to patients and doctors.
Cipro Case Reviews
The nationwide law firm of Bernstein Liebhard LLP is now offering free legal reviews to patients who were diagnosed with peripheral neuropathy that may be associated with their use of Cipro. To learn more about the litigation involving this drug, please call (888) 994-5118.
FDA Issues New Cipro Warning
May 2016: The U.S. Food & Drug Administration (FDA) is updating the boxed warning for Cipro and other systemic fluoroquinolones to state that the drugs are generally too dangerous for patients with sinusitis, bronchitis and uncomplicated urinary tract infections who have other treatment options. Their risks include issues affecting the tendons, muscles, joints, nerves and central nervous system that can occur together, and that may be permanent. Read More
Cipro Litigation News
- January 2017: Lawsuits filed on behalf of individuals who developed peripheral neuropathy allegedly related to the use of Cipro could start going to trial next year. Per an Order issued in the U.S. District Court, District of Minnesota, on January 17th, the Court intends to convene two Cipro bellwether trials on December 3, 2018, and April 8, 2019. Read More
- October 2016: The federal court overseeing Cipro lawsuits and other claims involving fluoroquinolone antibiotics and peripheral neuropathy has scheduled a Science Day for January 17, 2017. The event will allow plaintiffs and defendants to bring the Court up to speed on the medical and scientific issues central to the litigation. Read More
- August 2016: A Defendant fact sheet has been approved for use in the federal fluoroquinoline litigation. Such documents are utilized in large, centalized proceedings to standardize discovery, and generally takes the place of written interrogatories. A similar Plaintiff’s’ Fact Sheet was approved by the Court in April 2016. Read More
- August 2016: The federal court overseeing hundreds of peripheral neuropathy lawsuits involving Cipro and other fluoroquinolone antibiotics has declined to rule on a remand motion filed by a group of California plaintiffs. According to an Order issued in the U.S. District Court, District of Minnesota , the judge presiding over the centralized proceeding deferred his decision until he can review information underlying the plaintiffs’ pleadings against McKesson Corp., a California-based pharmaceutical distributor. All of the plaintiffs allegedly developed peripheral neuropathy due to their use of Cipro, Levaquin and various generic fluoroquinolones. Read More
- June 2016: Plaintiffs who have filed cases in the federal fluoroquinolone litigation underway in Minnesota have been granted leave to amend their Master Complaint to reflect the latest FDA label update. According to Minutes from the proceeding’s June 21st Status Conference, the Court found that doing so would not greatly expand the scope of the litigation. Read More
- May 2016: A Status Conference was convened in the federal fluoroquinolone litigation on May 18th, at which time it was reported that more than 400 peripheral neuropathy lawsuits involving Cipro, Avelox, and Levaquin had been filed nationwide. These included 383 cases pending in the U.S District Court, District of Minnesota, and an additional 39 claims that have been filed in the Philadelphia Court of Common Pleas. Minutes from the conference indicate that the Pennsylvania judge overseeing those lawsuits would be interested in coordinating with the federal multidistrict litigation. Read More
- April 2016: An Intitial Case Management Plan issued in the federal multidistrict litigation on April 26th sets forth protocols and limitations for discovery during the early stages of the proceeding. Among other things, the plan require that fact discovery in Cipro lawsuits be completed by September 29, 2017. Read More
- April 2016: The federal litigation overseeing nearly 400 fluoroquinolone peripheral neuropathy cases, including dozens of Cipro lawsuits, convened a Status Conference on April 21st. A number of is issues were addressed, including matters pertaining to bellwether trials, an initial case management plan, and scheduling of Science Day. Read More.
- February 2016: Minutes from a Status Conference held in the federal fluoroquinolone litigation on February 24th indicate that 425 peripheral neuropathy cases have been filed in the U.S. District Court, District of Minnesota. These include nearly 200 that name Bayer, the manufacturer of Cipro, as a defendant. Read More
- February 2016: A Pennsylvania state court has rejected a motion to have all peripheral neuropathy lawsuit filed in the state against the manufacturers of Cipro and other name-brand fluoroquinolones centralized in a single mass tort proceeding. Read More
- December 2015: A petition has been introduced in Pennsylvania to create a mass tort program in the Philadelphia Court of Common Pleas for all fluoroquinolone peripheral neuropathy lawsuits filed in the state. The petition points out that at least 30 such cases are pending in Pennsylvania courts, including a number that involve Cipro . Read More
- August 2015: The U.S. Judicial Panel on Multidistrict Litigation (JPML) has centralized all federal fluoroquinolone lawsuits involving peripheral neuropathy in the U.S. District Court, District of Minnesota. Read More
- July 2015: Oral arguments were heard on a motion to transfer all federal product liability lawsuits involving Levaquin and other fluoroquinolones to a single multidistrict litigation. Plaintiffs who favor the proposal assert that hundreds of similar lawsuits will eventually be filed, and argued that consolidation of the docket would reduce duplicative discovery, avoid conflicting pretrial rulings and better serve the convenience of the parties, witnesses and the courts. Read More.
Cipro and Peripheral Neuropathy
Since 2004, the labels for Cipro and other fluoroquinolone antibiotics have included mention of peripheral neuropathy. But in 2013, the U.S. Food & Drug Administration (FDA) ordered stronger warnings, after a review determined that the drugs’ labels did not adequately describe the rapid onset of the condition, or the potential for permanence. The agency also required that language characterizing peripheral neuropathy as a rare occurrence be deleted.
Peripheral neuropathy is nerve damage that causes injury to the nerves that carry messages between the brain, spinal cord, and body. Symptoms of this condition include:
- Paresthesia (tingling, prickling, etc. in the extremities)
- Burning sensation or freezing pain
- Sharp, jabbing pain
- Extreme sensitivity to touch
- Muscle weakness
- Decreased muscle coordination
- Problems walking
Plaintiffs who have filed Cipro lawsuits claim that they may have avoided this debilitating complication had Bayer AG provided doctors and patients with more accurate peripheral neuropathy warnings. Among other things, they point out that the connection between peripheral neuropathy and fluoroquinolones was recognized in 2001, when a study published in the Annals of Pharmacotherapy detailed 45 cases of the condition among people treated with the antibiotics. In more than half the cases, peripheral neuropathy symptoms persisted for a year or more. More than 80% were described as severe.
Call Now to Arrange Your Cipro Legal Review
Cipro patients who were diagnosed with peripheral neuropathy may be entitled to compensation for medical bills, lost wages, emotional distress and more. To arrange for a free, no-obligation Cipro lawsuit review, please contact our office today at (888) 994-5118.
Last Modified: January 26, 2017